{"id":"W4410803724","doi":"10.1200/jco.2025.43.16_suppl.1062","title":"Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech","keywords":"Medicine; Pharmacokinetics; Paclitaxel; Pharmacology; Internal medicine; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001060412,0.001562503,0.002524128,0.0005760586,0.0004432907,0.001464136,0.001216166,0.001289588,0.004074265],"category_scores_gemma":[0.0007119292,0.0008553092,0.001387213,0.0007219986,0.0008501027,0.0008938527,0.0004194203,0.004000349,0.0016225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001216258,"about_ca_system_score_gemma":0.002287783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001645771,"about_ca_topic_score_gemma":0.003657925,"domain_scores_codex":[0.9996388,0.000145132,0.00001874491,0.00006778887,0.00003182851,0.00009772525],"domain_scores_gemma":[0.9993057,0.00007565501,0.0001281182,0.00007151897,0.0000398387,0.0003792637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7008697,0.1381865,0.006905141,0.0008271104,0.001474942,0.000306687,0.0003852893,0.003884757,0.05943025,0.0003630562,0.005245492,0.08212116],"study_design_scores_gemma":[0.4654482,0.5121052,0.01033409,0.00004278675,0.0006421478,0.0003550441,0.00009262595,0.001607798,0.005499194,0.000241915,0.003596473,0.00003449629],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857449,0.00174658,0.0009765922,0.0004076037,0.0001429866,0.005485962,0.001861153,0.000187099,0.003447156],"genre_scores_gemma":[0.9811779,0.001879171,0.002080368,0.0008537471,0.0001651156,0.005393527,0.004652656,0.00007696198,0.003720503],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004074265,"threshold_uncertainty_score":0.01362979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08265775153649609,"score_gpt":0.5225800354404776,"score_spread":0.4399222839039815,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}